Executive Summary

Company Profile

Eurofins Scientific is a life sciences company operating laboratories in 30 countries to provide a comprehensive range of analytical testing services drawing on the latest developments in biotechnology. The Group specialises in delivering analytical testing and advisory services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors. With about $ 800 million in annual sales, Eurofins believes it is the global leader in food testing, belongs to the leading global laboratory groups serving the pharmaceutical industry and is number one in Europe in the environmental testing field.

Short History

Eurofins Scientific was founded in 1987 to market the SNIF-NMR technology, a patented analytical method used to verify the origin and purity of several types of food and beverages in cases where traditional testing methods would fail to detect a sophisticated fraud. Within a 20-year period, the Group has grown from a start-up company with 12 employees to become an international network of over 150 laboratories located in Europe, the USA, Asia and South-America employing about 8,000 staff. With a portfolio of over 25,000 reliable analytical methods and performing more than 80 million assays per year to establish the safety, composition, authenticity, origin, traceability, identity and purity of biological substances, the Eurofins Group is now a leading global provider of bioanalytical services.

Eurofins is one of the fastest growing companies in Europe: since its IPO on the French stock exchange in 1997, Eurofins’ sales have increased by more than 50% each year (in compound average) to € 633 m in 2008. The shares of Eurofins Scientific are traded on NYSE Euronext Paris and Deutsche Börse/XETRA (Frankfurt). Eurofins belongs to the following indices: NYSE Euronext SBF 250, Next150, Next Biotech, SRD and Compartiment B.

Recent Developments

In the first half of 2008, in a strong bioanalytical testing market Eurofins has continued to follow its strategy of building a sustainable business for the long term through: i) expanding and modernising existing facilities (France, USA, Brazil, China); ii) gaining new accreditations as well as renewal and extension of existing ones (GMO, agroscience, forensics); iii) the strengthening of its recently established areas (China, Sweden, Finland, Italy); iv) the integration and optimisation of acquired facilities (Scandinavia, USA); v) the ongoing rolling out of standardized IT systems for laboratory management and Group-wide marketing (ComLIMS and eLIMS).

The Group has made good progress in the integration of Analycen in all three countries where that company was active: Denmark, Sweden, Norway, has opened a new laboratory in Rotterdam and is developing a carbohydrate competence centre in the Netherlands.

Focused acquisitions increase the range of Eurofins offering in several markets. They include: Programma Ambiente in Italy, Institut Louise Blanquet in France and Defence Forensics in the UK.

Eurofins has developed many new analytical testing methods and has participated in or led several R&D projects in association with government bodies, industry and universities. Drawing on its world-class Competence Centres network and its expertise, Eurofins was able to develop further cross-selling business and won several outsourcing contracts for example with the Raisio Group.

Future Plans

Eurofins intends to strengthen its global position as a leading bioanalysis laboratory group serving the pharmaceutical, food and environmental industries and aims to become a global market leader in this field of applied life sciences. To achieve this, the Group has set an ambitious revenue objective of €1 billion by 2011.

The Group is committed to supporting its clients’ objectives of ensuring that their products reach the best possible quality and safety levels in all markets in which they operate. Eurofins intends to continue to develop, acquire or license the most comprehensive range of state-of-the-art analytical technologies as well as expand its geographical reach in order to support its clients’ increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.